This increased utilization, is being driven by favorable reimbursement, an aging population, and clinical results that are at least as good, if not better, than most surgery. For quite some time, customers and prospects alike have been asking for new ways to add SRT to their practices. As always, we listen closely to our market and we're delighted to meet their needs with highly competitive offering. This new recurring revenue model complements, our capital equipment sales model, which you'll recall was enhanced with our fair market value lease, which we introduced in 2021. This new model provides recurring revenue to Sensus and expands our market by providing another viable option to bring SRT, to dermatology practices. During the fourth quarter, we made our first placement under this model.

We've been carefully preparing this recurring revenue model over the past year, making sure that the economics work for both our customers and for Sensus, and ensuring we were abiding by all applicable laws and regulations. Note also that the capabilities of SRT-100 Vision with image-guided ultrasound and Sentinel technology make the recurring revenue model possible. I've mentioned on previous quarterly calls that, this advanced technology is expected, to play a key role in our growth, and now you may understand why we've been so excited with Sentinel. This is our HIPAA-compliant software with clinical, billing, and asset management utility that also allows us to track utilization in real time. This technology is ideal for better managing dermatology clinics, for all of our customers and is a Sensus Healthcare exclusive.

During 2023, we also introduced an important new and improved high-resolution ultrasound technology, to provide see and treat capability. This leads to great clinical outcomes, because the physician can actually see the impact of each treatment on the lesion and lesion resolution after treatment. We're looking forward to more directly benefiting from the SRT treatment growth rates we've seen. Recall that earlier in 2023, we found in our surveys of Medicare that SRT experienced a 27% year-over-year treatment growth rate, for the six years we reviewed. Should this growth rate continue, SRT will soon become the treatment of choice for non-melanoma skin cancer. We're very excited to be interacting with customers and prospects during the coming weeks.

This weekend, we'll be showcasing our SRT products, in particular the SRT-100 Vision IG-SRT system and the Sentinel technology and Sensus cloud capabilities at the South Beach Symposium, which begins today in Miami. We'll also be at the Winter Clinical, also in Miami, beginning February 16. We'll follow those conferences up with the American Academy of Dermatology's Annual Meeting being held March 8 through 12 in San Diego, where we will have a very strong presence. While dermatology is our primary market, we continue to engage with the radiation oncology market, which is mainly a hospital-based channel. As mentioned last quarter, we've had good success in this area, having recently placed an SRT system at Cape Cod Hospital. As a reminder, this market has a longer sales cycle as we continue to see increased interest.

With respect to the transdermal infusion product, we filed our 510(k) application with the U.S. FDA in October of 2023, and are hopeful that we'll be hearing from the agency in the coming weeks. This system will, for example, allow platelet-rich plasma, or PRP, to be applied to the scalp in a pain-free hair restoration experience. In addition, posters have already been presented on the application of hyperhidrosis, or overactive sweat glands. Our transdermal system includes Sentinel IT solution capabilities, as do all six of our Sensus-branded aesthetic smart lasers. We will be exhibiting our TDI product at the upcoming dermatology trade shows as a works-in-progress. With those remarks, I'll turn the call over to Michael Sardano, who, in addition to his duties as President and General Counsel, joined our Board of Directors last week.

He'll give you a brief update on our international business, and talk about our new collaboration with CureRays. Michael?

Michael Sardano: Thanks, Joe. We've spent the last year working to open up new international territories, which requires both regulatory approvals and strategic engagement of distributors. We continue, to support our international distributors across Asia, Europe, and the Middle East, and we are developing a number of promising opportunities, to supplement our strong demand in China. We sold a total of 13 SRT systems internationally in 2023, which includes sales to three new territories for Sensus during the year, namely Ireland, Guatemala, and Turkey. As I stated in our last earnings call in November, our plan, is to expand our Latin American, European, and Asian footprint as quickly as possible, with Brazil and Japan being longer-term prospects, as they are highly regulated.

Our goal is to open two to three new territories per year, which we achieved in 2023. Turning back to the U.S. market, earlier this week we announced a collaboration with CureRays. CureRays is led by two radiation oncologists, Dr. Mohammad Khan, who is on the Sensus Medical Advisory Board and is Vice Chair for Radiation Oncology Education at Emory University in Atlanta, and Dr. Clayton Hess, who is the Director of Dignity Health at Sierra Nevada Memorial Hospital in California. CureRays has purchased an SRT-100 Vision and will be treating patients out of their California headquarters. CureRays is focused on three main endeavors, the treatment of patients for non-melanoma, skin cancer and keloids, treatment oversight for Sensus' dermatology customers, and conducting clinical trials with the use of Sensus' SRT technology.

CureRays will be instrumental, to our recurring revenue model, and we are very excited to be partnering with them. With that, I'll turn the call over to Javier for a discussion of our financial results.

Javier Rampolla: Thanks, Michael, and good afternoon, everyone. As Joe mentioned, our revenues for the fourth quarter of 2023 were $12.6 million, and this compares with revenues of $13.1 million a year ago and revenues of $3.9 million in the third quarter of 2023. The decrease versus the prior year, reflects a lower number of SRT units sold. Gross profit for the fourth quarter of 2023 was $7.8 million, or 62.3% of revenues, compared with gross profit of $8.4 million, or 63.7% of revenues, for the fourth quarter of 2022. The decrease was primarily due to the lower number of units sold in the 2023 quarter. Selling and marketing expense for the fourth quarter of 2023 was $0.6 million, compared with $1.6 million for the fourth quarter of 2022.

The decrease was primarily attributable to lower compensation expense, partially offset by higher tradeshow costs. General and administrative expense for the fourth quarter of 2023, was $1 million, compared with $1.4 million for the fourth quarter of 2022. The decrease was, due to lower compensation expense in the 2023 quarter and higher budget expense in the prior year quarter. Research and development expense for the fourth quarter of 2023 was $0.7 million, compared with $1.2 million in the same quarter last year. The decrease was primarily, due to the completion of development of a drug delivery system for the aesthetic market. We have submitted a 510(k) application to the U.S. Food and Drug Administration, and have completed most of the work on this project.

Other income of $0.2 million for the fourth quarter of 2023, was mostly related to interest income and was unchanged from the fourth quarter of 2022. Net income for the fourth quarter of 2023, was $4.2 million, or $0.26, for diluted share, and this compares with net income of $2.8 million, or $0.17, per diluted share for the fourth quarter of 2022. Adjusted EBITDA, which we define as earnings before interest, taxes, depreciation, amortization, and stock-compensation expense, was $5.7 million for the fourth quarter of 2023, up from $4.3 million for the fourth quarter of 2022. Let me touch on - our full year financial results highlights. Revenues for 2023 were $24.4 million, compared with $44.5 million for 2022, reflecting a lower number of percentage units sold, as customers deferred purchases, due to microeconomics conditions and lower sales to our customer in 2023.

Gross profit was $14.1 million for 2023, or 57.6% of revenues, compared with $29.6 million, or 66.5% of revenues for 2022, reflecting a lower number of units sold and higher cost charged by vendors in 2023. Selling and marketing expense was $5.6 million for 2023, compared with $6.3 million for 2022, due to lower compensation expense offset by higher threshold expenses. General and administrative expense was $5.2 million for 2023, compared with $5 million for 2022, with the increase reflecting higher professional fees and compensation expense. R&D was $3.7 million for 2023, compared with $3.5 million for 2022, with an increase largely due to expense related to the development of a drug delivery system for aesthetic use. Other income net of $1 million for 2023, was mostly related to interest income.

Other income net of $13.2 million for 2022 was related primarily to the gain of $4.8 million on the sale of a non-core asset. Net income for 2023 was $0.5 million, or $0.03 per diluted share, and this compares with net income for 2022 of $24.2 million, or $1.46 per diluted share. Net income for 2022 includes a $12.8 million gain on the sale of a non-core asset. Adjusted EBITDA for 2023 was $0.3 million, compared with $28.1 million for 2022. Turning now to our balance sheet. Cash and cash equivalents as of December 31, 2023 were $23.1 million versus $25.5 million as of December 31, 2022. The company had no outstanding borrowings under its revolving out of credit as of year-end 2023 or 2022. We built finished goods and inventory and prepaid for materials earlier during 2023, in part to get ahead of any price increases and to prepare for the anticipated growth, especially from the recovery revenue models.

At the end of 2023, inventories were $11.9 million, well above $3.5 million, as of the end of 2022. Prepaid inventory was $3 million at the end of 2033, versus $6.6 million at year end 2022. Our cash spend continues to be very focused and highly disciplined. Nevertheless, our balance sheet positions as well to take advantage of the compelling growth opportunities we may come across, or that we may create ourselves. As a final comment, please see the table in the news release, we issued earlier today for the reconciliation of GAAP to non-GAAP financial measures. With that, I'll turn the call back to Joe.

Joe Sardano: Thanks, Javier and Michael. The ROI for our premium SRT system under our fair market value leasing program continues to be compelling, and although it's early, our initial introductions of our recurring revenue model, are being met with a great deal of interest. With the many upcoming medical meetings, I'm sure we'll gain momentum for this program as the word spreads. Published studies have shown that SRT clinical results are as good or better than most surgery and certainly it's non-invasive, leaving no scar. There's no question that SRT and IG-SRT have become the number one option for surgery. As I've said many times, we are still in the early stages of tapping the enormous market opportunity for SRT just in non-melanoma skin cancer and keloids.

Our systems are well positioned in a large and largely untapped market. They provide a compelling alternative, to surgery for millions of patients and arguably the only solution to prevent the recurrence of keloids following excision. As an overlay to all of this, an estimated one in five Americans will develop skin cancer during their lifetime. This tells us that nearly 70 million people will have non-melanoma skin cancer. So clearly, there's a need for our SRT systems both now and even more so in the future. We are confident that Sensus is positioned for success and we have a great team to drive growth and implement our strategies. With those comments, I thank you for your time and attention and now operator, we're ready to take questions.

Operator: [Operator Instructions] And our first question will come from Alex Nowak with Craig-Hallum Capital. Please go ahead.

See also 12 Highest-Paid Women CEOs and 15 Best Cities for Hedge Fund Managers.

To continue reading the Q&A session, please click here.